Originally published Friday, February 23, 2007 at 12:00 AM
Ikaria announces major acquisition
Seattle biotech Ikaria said Thursday it is acquiring INO Therapeutics in a merger that is valued at $670 million. As part of the deal, the...
Seattle Times technology reporter
Seattle biotech Ikaria said Thursday it is acquiring INO Therapeutics in a merger that is valued at $670 million.
As part of the deal, the combined company, called Ikaria Holdings, secured an undisclosed amount of debt and raised $300 million in capital to pay for the acquisition.
At that level, the investment could be considered the largest round of financing in biotech history, outdoing the $273.7 million raised by Reliant Pharmaceuticals in 2003, according to VentureOne, a Dow Jones company.
However, VentureOne is still determining whether Ikaria's round will be categorized as a venture-capital investment, a category typically reserved for early-stage companies, or as a private-equity deal, which denotes a more mature company.
When the deal closes — expected about April — Ikaria Holdings will have 300 employees and be based in Clinton, N.J. The research and development facilities will remain in Seattle, where there are now about 20 employees.
Robert Nelsen, a partner at ARCH Venture Partners, which participated in the deal as an original investor in Ikaria, said that the company will be hiring aggressively here.
Other investors involved include New Mountain Capital, Venrock Associates, Altitude Life Science Ventures, Washington Research Foundation and Alexandria Equities.
Ikaria and INO have different backgrounds but are coming together based on using the same technology.
Both deliver drugs in the form of gas, rather than by pill or injection, said David Shaw, who was on Ikaria's board and will become the chairman and chief executive of the combined company.
Ikaria, founded in 2005 and spun out from the Fred Hutchinson Cancer Research Center, had raised $11 million in venture capital.
INO Therapeutics, which has $160 million in annual revenue and is profitable, was owned by The Linde Group, an engineering company that trades on the German stock exchange (Linde will continue to own 17 percent in Ikaria Holdings).
INO produces a gaseous drug to treat premature babies who have difficulty getting oxygen into their blood, often called the "blue baby" syndrome.
![]()
Ikaria is working on producing a drug that would allow critical-care patients to enter a suspended state until they are able to receive treatment.
Shaw said Ikaria will be able to gain from INO's experience in getting a gas-based drug through the U.S. government approval process; INO claims to have the only Federal and Drug Administration approved drug in the form of gas. At the same time, INO expects to gain from Ikaria's research expertise.
Nelsen said the two center on serving critical-care patients, a niche that doesn't get much attention by the medical-research community.
"We've been working on [the deal] for about a year, and we really think there's a real opportunity because there's been very little innovation in the critical-care space for the last 50 years," he said.
"Ikaria's technology could buy additional time when you are in acute situation, like a heart attack, stroke or when you are bleeding to death."
Tricia Duryee: 206-464-3283 or tduryee@seattletimes.com
UPDATE - 09:46 AM
Exxon Mobil wins ruling in Alaska oil spill case
UPDATE - 09:32 AM
Bank stocks push indexes higher; oil prices dip
UPDATE - 08:04 AM
Ford CEO Mulally gets $56.5M in stock award
UPDATE - 07:54 AM
Underwater mortgages rise as home prices fall
NEW - 09:43 AM
Warner Bros. to offer movie rentals on Facebook

Entertainment | Top Video | World | Offbeat Video | Sci-Tech
- Lakewood cop accused of embezzling $150K meant for slain officers' families
- 3 big health insurers stockpile $2.4 billion as rates keep rising
- Agency set to investigate handling of 911 call about Josh Powell
- Quick decisions: How Washington hired its new football staff
- Historic day for gay marriage as another fight looms
- Justin Wilcox's versatile defensive style is the right fit for Huskies | Jerry Brewer
- Social worker recounts minutes before Powell fire
- It's Terrence Time: Enigmatic Ross leads Huskies
- $25B settlement reached over foreclosure abuses
- Club promoter convicted in brutal 2010 murder of Des Moines prostitute
- Gay-marriage bill passes House, awaits Gregoire's signature
488 - Historic day for gay marriage as another fight looming
369 - Wanted in Seattle classrooms: more teachers of color
347 - 3 big health insurers stockpile $2.4 billion as rates keep rising
244 - Council members get briefing on arena proposal, minus details
225 - AP Source: Obama to change birth control rule
213 - Oregon live game thread
155 - Pac-12 picks ... including the UW game
140 - Worker: Josh Powell told son he had 'surprise'
108 - Rough road again
100
- Wanted in Seattle classrooms: more teachers of color
- State Medicaid program to stop paying for unneeded ER visits
- 3 big health insurers stockpile $2.4 billion as rates keep rising
- Economy, blogs give survivalists new reason to look to Northwest
- State's share of mortgage settlement: $648 million
- One man's audacious pursuit of sailing history
- Darren Berg gets 18-year sentence for Ponzi scheme
- Bellevue College adds a third bachelor's degree program
- $25B settlement reached over foreclosure abuses
- 'Gauguin and Polynesia': dazzling mix-and-match | Art review
